The three-signal paradigm tries to capture how the innate immune system instructs adaptive immune responses in three well-defined actions: (1) presentation of antigenic peptides in the context of MHC ...

Through cytokine screening, we identified that interleukin-1β (IL-1β), a key mediator of inflammation, inhibits syncytia formation mediated by various SARS-CoV-2 strains. Mechanistically, IL-1β ...

Second, they investigated the IL-1 signaling pathway in detail, using knockouts or pharmacological perturbation to understand the signaling proteins responsible for blocking cell fusion. They found ...

HCW Biologics Inc. (HCWB) a clinical-stage biopharmaceutical company, Monday said that the Food and Drug Administration (FDA)has ...

This study will evaluate HCW9302 in patients with moderate to severe alopecia areataMIRAMAR, Fla., Feb. 03, 2025 (GLOBE ...

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...